Publications
Professor Bäckhed and his group are co-authors of over 200 research articles in international journals. The high impact publications are also made possible by a long list of fruitful international collaborations with groups that are experts in completely different fields.
“We have commitment to work hard with our projects before publication to make a high and durable impact presenting mechanistic and clinical relevant findings.”
Selected publications
For full list of publications : ORCID: 0000-0002-4871-8818
- Gut microbiota responses to bariatric surgery are associated with metabolic outcomes and type 2 diabetes remission
Olsson, L.M., Heidi Borgeraas. H., Chakaroun, R.M., Hofsø, D., Hertel, J.K., Dwibedi, D., Mitteregger, M., Juul Holst, J., Tremaroli, V., Hjelmesæth J. & Bäckhed F. Nature Metabolism (2026) - Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions
Chakaroun, R.M., Pradhan, M., Björnson, E., Arvidsson, D., Fridolfsson, J., Gummesson, A., Schoeler, M., Mitteregger M., Smith, G.J., Larsson, I., Mats Börjesson, Blüher, M., Uhlén, M., Stumvoll, M., Bergström, G., Tremaroli, V. & Bäckhed, F. Nature Medicine (2026) - Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes
Wu, H., Lv, B., Zhi, L., Shao, Y., Liu, X., Mitteregger, M., Chakaroun, R., Tremaroli, V., Hazen, S.L., Wang, R., Bergström, G. & Bäckhed, F. Nature Medicine (2025) - Synergy and oxygen adaptation for development of next-generation probiotics
Khan MT, Dwibedi C, Sundh D, Pradhan M, Kraft JD, Caesar R, Tremaroli V, Lorentzon M, Bäckhed F. Nature (2023)
We developed innovative technology to produce next-generation probiotics for human consumption from extremely oxygen sensitive human gut bacteria. In the article we describe the production of a formulation containing the anti-inflammatory Faecalibacterium prausnitzii, which is a dominant human gut bacterium, depleted in both inflammatory bowel diseases and metabolic diseases. - 6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice.
Makki, K., Brolin, H., Petersen, N., Henricsson, M., Christensen, D.P., Khan, M.T., Wahlström, A., Bergh, P.O., Tremaroli, V., Schoonjans, K., Marschall, H.U., Bäckhed, F.
Gut (2023)
Here we unexpectedly demonstrated that in presence of dietary fiber the gut microbiota produces 6α-hydroxylated bile acids that improve glucose metabolism by activating TGR5/GLP-1 signaling. Illustrates our mechanistic/cell signaling work. - The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study
Wu, H., Tremaroli, V., Schmidt, C., Lundqvist, A., Olsson, L.M., Krämer, M., Gummesson, A., Perkins, R.,Bergström, G., Bäckhed, F. Cell Metabolism (2020)
Largest study on diabetes and microbiome to date demonstrating that the microbiota is altered in pre-diabetes and type 2 diabetes independent of medication. - Microbe-produced imidazole propionate impairs insulin signaling via p38g/p62/mTORC1
Koh, A., Molinaro, A., Ståhlman, M., Khan, M.T., Schmidt, C., Mannerås-Holm, L., Wu, H., Carreras, A., Jeong, H., Olofsson, L., Bergh, P., Gerdes, V., Hartstra, A, de Brauw, D., Perkins, R., Nieuwdorp, M., Bergström, G., Bäckhed, F. Cell (2018)
Identified imidazole propionate to be elevated in subjects with T2D as well as showing causality and identified the underlying signalling mechanism.